ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Long-acting Beta Agonists Market Research Report 2025
Published Date: May 2025
|
Report Code: QYRE-Auto-32P13724
Home | Market Reports | Health| Pharmacy| Drugs & Medications
Global Long acting Beta Agonists Market Research Report 2023
BUY CHAPTERS

Global Long-acting Beta Agonists Market Research Report 2025

Code: QYRE-Auto-32P13724
Report
May 2025
Pages:83
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Astrazeneca plc
Chiesi
Boehringer Ingelheim
GSK
Novartis
TEVA
Organon

Long-acting Beta Agonists Market Size

The global market for Long-acting Beta Agonists was valued at US$ 4667 million in the year 2024 and is projected to reach a revised size of US$ 5800 million by 2031, growing at a CAGR of 3.2% during the forecast period.

Long-acting Beta Agonists Market

Long-acting Beta Agonists Market

Long-Acting Beta Agonists (LABAs) are inhaled medications that are used in the treatment of asthma and chronic obstuctive pulmonary disease (COPD).
The inhalation combination product market is driven by the increasing prevalence of respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD) and the demand for more effective and convenient treatment options. Inhalation combination products offer a combination of two or more medications in a single device, providing patients with better disease management and improved treatment adherence. These products offer advantages such as simplified dosing regimens, enhanced efficacy, and reduced side effects compared to multiple separate inhalers. Additionally, advancements in inhalation technology, such as metered-dose inhalers and dry powder inhalers, have further fueled the adoption of combination products. However, the market also faces challenges, including the complexity of formulation development and the need for rigorous testing to ensure compatibility and stability of the combined medications. Moreover, regulatory requirements for combination products can be more stringent than individual drugs, making the approval process more challenging. To succeed in this market, manufacturers must invest in research and development to optimize combination therapies, address regulatory concerns, and educate healthcare professionals and patients about the benefits of inhalation combination products.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Long-acting Beta Agonists, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Long-acting Beta Agonists.
The Long-acting Beta Agonists market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Long-acting Beta Agonists market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Long-acting Beta Agonists manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of Long-acting Beta Agonists Market Report

Report Metric Details
Report Name Long-acting Beta Agonists Market
Accounted market size in year US$ 4667 million
Forecasted market size in 2031 US$ 5800 million
CAGR 3.2%
Base Year year
Forecasted years 2025 - 2031
Segment by Type
  • Serevent
  • Foradil
  • Striverdi
  • Other
Segment by Application
  • COPD
  • Asthma
  • Other
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company GSK, AstraZeneca, Chiesi, Boehringer Ingelheim, Novartis, Teva, Organon
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Detailed analysis of Long-acting Beta Agonists manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 3: Sales, revenue of Long-acting Beta Agonists in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
  • Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 9: The main points and conclusions of the report. 

FAQ for this report

How fast is Long-acting Beta Agonists Market growing?

Ans: The Long-acting Beta Agonists Market witnessing a CAGR of 3.2% during the forecast period 2025-2031.

What is the Long-acting Beta Agonists Market size in 2031?

Ans: The Long-acting Beta Agonists Market size in 2031 will be US$ 5800 million.

Who are the main players in the Long-acting Beta Agonists Market report?

Ans: The main players in the Long-acting Beta Agonists Market are GSK, AstraZeneca, Chiesi, Boehringer Ingelheim, Novartis, Teva, Organon

What are the Application segmentation covered in the Long-acting Beta Agonists Market report?

Ans: The Applications covered in the Long-acting Beta Agonists Market report are COPD, Asthma, Other

What are the Type segmentation covered in the Long-acting Beta Agonists Market report?

Ans: The Types covered in the Long-acting Beta Agonists Market report are Serevent, Foradil, Striverdi, Other

Recommended Reports

Asthma Therapeutics

COPD and Respiratory

Inhalation Devices

1 Long-acting Beta Agonists Market Overview
1.1 Product Definition
1.2 Long-acting Beta Agonists by Type
1.2.1 Global Long-acting Beta Agonists Market Value Comparison by Type (2024 VS 2031)
1.2.2 Serevent
1.2.3 Foradil
1.2.4 Striverdi
1.2.5 Other
1.3 Long-acting Beta Agonists by Application
1.3.1 Global Long-acting Beta Agonists Market Value by Application (2024 VS 2031)
1.3.2 COPD
1.3.3 Asthma
1.3.4 Other
1.4 Global Long-acting Beta Agonists Market Size Estimates and Forecasts
1.4.1 Global Long-acting Beta Agonists Revenue 2020-2031
1.4.2 Global Long-acting Beta Agonists Sales 2020-2031
1.4.3 Global Long-acting Beta Agonists Market Average Price (2020-2031)
1.5 Assumptions and Limitations
2 Long-acting Beta Agonists Market Competition by Manufacturers
2.1 Global Long-acting Beta Agonists Sales Market Share by Manufacturers (2020-2025)
2.2 Global Long-acting Beta Agonists Revenue Market Share by Manufacturers (2020-2025)
2.3 Global Long-acting Beta Agonists Average Price by Manufacturers (2020-2025)
2.4 Global Key Players of Long-acting Beta Agonists, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Long-acting Beta Agonists, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Long-acting Beta Agonists, Product Type & Application
2.7 Global Key Manufacturers of Long-acting Beta Agonists, Date of Enter into This Industry
2.8 Global Long-acting Beta Agonists Market Competitive Situation and Trends
2.8.1 Global Long-acting Beta Agonists Market Concentration Rate
2.8.2 The Global 5 and 10 Largest Long-acting Beta Agonists Players Market Share by Revenue
2.8.3 Global Long-acting Beta Agonists Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Long-acting Beta Agonists Market Scenario by Region
3.1 Global Long-acting Beta Agonists Market Size by Region: 2020 Versus 2024 Versus 2031
3.2 Global Long-acting Beta Agonists Sales by Region: 2020-2031
3.2.1 Global Long-acting Beta Agonists Sales by Region: 2020-2025
3.2.2 Global Long-acting Beta Agonists Sales by Region: 2026-2031
3.3 Global Long-acting Beta Agonists Revenue by Region: 2020-2031
3.3.1 Global Long-acting Beta Agonists Revenue by Region: 2020-2025
3.3.2 Global Long-acting Beta Agonists Revenue by Region: 2026-2031
3.4 North America Long-acting Beta Agonists Market Facts & Figures by Country
3.4.1 North America Long-acting Beta Agonists Market Size by Country: 2020 VS 2024 VS 2031
3.4.2 North America Long-acting Beta Agonists Sales by Country (2020-2031)
3.4.3 North America Long-acting Beta Agonists Revenue by Country (2020-2031)
3.4.4 United States
3.4.5 Canada
3.5 Europe Long-acting Beta Agonists Market Facts & Figures by Country
3.5.1 Europe Long-acting Beta Agonists Market Size by Country: 2020 VS 2024 VS 2031
3.5.2 Europe Long-acting Beta Agonists Sales by Country (2020-2031)
3.5.3 Europe Long-acting Beta Agonists Revenue by Country (2020-2031)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Long-acting Beta Agonists Market Facts & Figures by Region
3.6.1 Asia Pacific Long-acting Beta Agonists Market Size by Region: 2020 VS 2024 VS 2031
3.6.2 Asia Pacific Long-acting Beta Agonists Sales by Region (2020-2031)
3.6.3 Asia Pacific Long-acting Beta Agonists Revenue by Region (2020-2031)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Long-acting Beta Agonists Market Facts & Figures by Country
3.7.1 Latin America Long-acting Beta Agonists Market Size by Country: 2020 VS 2024 VS 2031
3.7.2 Latin America Long-acting Beta Agonists Sales by Country (2020-2031)
3.7.3 Latin America Long-acting Beta Agonists Revenue by Country (2020-2031)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Long-acting Beta Agonists Market Facts & Figures by Country
3.8.1 Middle East and Africa Long-acting Beta Agonists Market Size by Country: 2020 VS 2024 VS 2031
3.8.2 Middle East and Africa Long-acting Beta Agonists Sales by Country (2020-2031)
3.8.3 Middle East and Africa Long-acting Beta Agonists Revenue by Country (2020-2031)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Long-acting Beta Agonists Sales by Type (2020-2031)
4.1.1 Global Long-acting Beta Agonists Sales by Type (2020-2025)
4.1.2 Global Long-acting Beta Agonists Sales by Type (2026-2031)
4.1.3 Global Long-acting Beta Agonists Sales Market Share by Type (2020-2031)
4.2 Global Long-acting Beta Agonists Revenue by Type (2020-2031)
4.2.1 Global Long-acting Beta Agonists Revenue by Type (2020-2025)
4.2.2 Global Long-acting Beta Agonists Revenue by Type (2026-2031)
4.2.3 Global Long-acting Beta Agonists Revenue Market Share by Type (2020-2031)
4.3 Global Long-acting Beta Agonists Price by Type (2020-2031)
5 Segment by Application
5.1 Global Long-acting Beta Agonists Sales by Application (2020-2031)
5.1.1 Global Long-acting Beta Agonists Sales by Application (2020-2025)
5.1.2 Global Long-acting Beta Agonists Sales by Application (2026-2031)
5.1.3 Global Long-acting Beta Agonists Sales Market Share by Application (2020-2031)
5.2 Global Long-acting Beta Agonists Revenue by Application (2020-2031)
5.2.1 Global Long-acting Beta Agonists Revenue by Application (2020-2025)
5.2.2 Global Long-acting Beta Agonists Revenue by Application (2026-2031)
5.2.3 Global Long-acting Beta Agonists Revenue Market Share by Application (2020-2031)
5.3 Global Long-acting Beta Agonists Price by Application (2020-2031)
6 Key Companies Profiled
6.1 GSK
6.1.1 GSK Company Information
6.1.2 GSK Description and Business Overview
6.1.3 GSK Long-acting Beta Agonists Sales, Revenue and Gross Margin (2020-2025)
6.1.4 GSK Long-acting Beta Agonists Product Portfolio
6.1.5 GSK Recent Developments/Updates
6.2 AstraZeneca
6.2.1 AstraZeneca Company Information
6.2.2 AstraZeneca Description and Business Overview
6.2.3 AstraZeneca Long-acting Beta Agonists Sales, Revenue and Gross Margin (2020-2025)
6.2.4 AstraZeneca Long-acting Beta Agonists Product Portfolio
6.2.5 AstraZeneca Recent Developments/Updates
6.3 Chiesi
6.3.1 Chiesi Company Information
6.3.2 Chiesi Description and Business Overview
6.3.3 Chiesi Long-acting Beta Agonists Sales, Revenue and Gross Margin (2020-2025)
6.3.4 Chiesi Long-acting Beta Agonists Product Portfolio
6.3.5 Chiesi Recent Developments/Updates
6.4 Boehringer Ingelheim
6.4.1 Boehringer Ingelheim Company Information
6.4.2 Boehringer Ingelheim Description and Business Overview
6.4.3 Boehringer Ingelheim Long-acting Beta Agonists Sales, Revenue and Gross Margin (2020-2025)
6.4.4 Boehringer Ingelheim Long-acting Beta Agonists Product Portfolio
6.4.5 Boehringer Ingelheim Recent Developments/Updates
6.5 Novartis
6.5.1 Novartis Company Information
6.5.2 Novartis Description and Business Overview
6.5.3 Novartis Long-acting Beta Agonists Sales, Revenue and Gross Margin (2020-2025)
6.5.4 Novartis Long-acting Beta Agonists Product Portfolio
6.5.5 Novartis Recent Developments/Updates
6.6 Teva
6.6.1 Teva Company Information
6.6.2 Teva Description and Business Overview
6.6.3 Teva Long-acting Beta Agonists Sales, Revenue and Gross Margin (2020-2025)
6.6.4 Teva Long-acting Beta Agonists Product Portfolio
6.6.5 Teva Recent Developments/Updates
6.7 Organon
6.7.1 Organon Company Information
6.7.2 Organon Description and Business Overview
6.7.3 Organon Long-acting Beta Agonists Sales, Revenue and Gross Margin (2020-2025)
6.7.4 Organon Long-acting Beta Agonists Product Portfolio
6.7.5 Organon Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Long-acting Beta Agonists Industry Chain Analysis
7.2 Long-acting Beta Agonists Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Long-acting Beta Agonists Production Mode & Process Analysis
7.4 Long-acting Beta Agonists Sales and Marketing
7.4.1 Long-acting Beta Agonists Sales Channels
7.4.2 Long-acting Beta Agonists Distributors
7.5 Long-acting Beta Agonists Customer Analysis
8 Long-acting Beta Agonists Market Dynamics
8.1 Long-acting Beta Agonists Industry Trends
8.2 Long-acting Beta Agonists Market Drivers
8.3 Long-acting Beta Agonists Market Challenges
8.4 Long-acting Beta Agonists Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
FEATURED COMPANIES
Astrazeneca plc
Chiesi
Boehringer Ingelheim
GSK
Novartis
TEVA
Organon
List of Tables
 Table 1. Global Long-acting Beta Agonists Market Value Comparison by Type (2024 VS 2031) & (US$ Million)
 Table 2. Global Long-acting Beta Agonists Market Value by Application (2024 VS 2031) & (US$ Million)
 Table 3. Global Long-acting Beta Agonists Market Competitive Situation by Manufacturers in 2024
 Table 4. Global Long-acting Beta Agonists Sales (K Units) of Key Manufacturers (2020-2025)
 Table 5. Global Long-acting Beta Agonists Sales Market Share by Manufacturers (2020-2025)
 Table 6. Global Long-acting Beta Agonists Revenue (US$ Million) by Manufacturers (2020-2025)
 Table 7. Global Long-acting Beta Agonists Revenue Share by Manufacturers (2020-2025)
 Table 8. Global Market Long-acting Beta Agonists Average Price (US$/Unit) of Key Manufacturers (2020-2025)
 Table 9. Global Key Players of Long-acting Beta Agonists, Industry Ranking, 2022 VS 2023 VS 2024
 Table 10. Global Key Manufacturers of Long-acting Beta Agonists, Manufacturing Sites & Headquarters
 Table 11. Global Key Manufacturers of Long-acting Beta Agonists, Product Type & Application
 Table 12. Global Key Manufacturers of Long-acting Beta Agonists, Date of Enter into This Industry
 Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
 Table 14. Global Long-acting Beta Agonists by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Long-acting Beta Agonists as of 2024)
 Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
 Table 16. Global Long-acting Beta Agonists Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 17. Global Long-acting Beta Agonists Sales by Region (2020-2025) & (K Units)
 Table 18. Global Long-acting Beta Agonists Sales Market Share by Region (2020-2025)
 Table 19. Global Long-acting Beta Agonists Sales by Region (2026-2031) & (K Units)
 Table 20. Global Long-acting Beta Agonists Sales Market Share by Region (2026-2031)
 Table 21. Global Long-acting Beta Agonists Revenue by Region (2020-2025) & (US$ Million)
 Table 22. Global Long-acting Beta Agonists Revenue Market Share by Region (2020-2025)
 Table 23. Global Long-acting Beta Agonists Revenue by Region (2026-2031) & (US$ Million)
 Table 24. Global Long-acting Beta Agonists Revenue Market Share by Region (2026-2031)
 Table 25. North America Long-acting Beta Agonists Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 26. North America Long-acting Beta Agonists Sales by Country (2020-2025) & (K Units)
 Table 27. North America Long-acting Beta Agonists Sales by Country (2026-2031) & (K Units)
 Table 28. North America Long-acting Beta Agonists Revenue by Country (2020-2025) & (US$ Million)
 Table 29. North America Long-acting Beta Agonists Revenue by Country (2026-2031) & (US$ Million)
 Table 30. Europe Long-acting Beta Agonists Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 31. Europe Long-acting Beta Agonists Sales by Country (2020-2025) & (K Units)
 Table 32. Europe Long-acting Beta Agonists Sales by Country (2026-2031) & (K Units)
 Table 33. Europe Long-acting Beta Agonists Revenue by Country (2020-2025) & (US$ Million)
 Table 34. Europe Long-acting Beta Agonists Revenue by Country (2026-2031) & (US$ Million)
 Table 35. Asia Pacific Long-acting Beta Agonists Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 36. Asia Pacific Long-acting Beta Agonists Sales by Region (2020-2025) & (K Units)
 Table 37. Asia Pacific Long-acting Beta Agonists Sales by Region (2026-2031) & (K Units)
 Table 38. Asia Pacific Long-acting Beta Agonists Revenue by Region (2020-2025) & (US$ Million)
 Table 39. Asia Pacific Long-acting Beta Agonists Revenue by Region (2026-2031) & (US$ Million)
 Table 40. Latin America Long-acting Beta Agonists Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 41. Latin America Long-acting Beta Agonists Sales by Country (2020-2025) & (K Units)
 Table 42. Latin America Long-acting Beta Agonists Sales by Country (2026-2031) & (K Units)
 Table 43. Latin America Long-acting Beta Agonists Revenue by Country (2020-2025) & (US$ Million)
 Table 44. Latin America Long-acting Beta Agonists Revenue by Country (2026-2031) & (US$ Million)
 Table 45. Middle East and Africa Long-acting Beta Agonists Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 46. Middle East and Africa Long-acting Beta Agonists Sales by Country (2020-2025) & (K Units)
 Table 47. Middle East and Africa Long-acting Beta Agonists Sales by Country (2026-2031) & (K Units)
 Table 48. Middle East and Africa Long-acting Beta Agonists Revenue by Country (2020-2025) & (US$ Million)
 Table 49. Middle East and Africa Long-acting Beta Agonists Revenue by Country (2026-2031) & (US$ Million)
 Table 50. Global Long-acting Beta Agonists Sales (K Units) by Type (2020-2025)
 Table 51. Global Long-acting Beta Agonists Sales (K Units) by Type (2026-2031)
 Table 52. Global Long-acting Beta Agonists Sales Market Share by Type (2020-2025)
 Table 53. Global Long-acting Beta Agonists Sales Market Share by Type (2026-2031)
 Table 54. Global Long-acting Beta Agonists Revenue (US$ Million) by Type (2020-2025)
 Table 55. Global Long-acting Beta Agonists Revenue (US$ Million) by Type (2026-2031)
 Table 56. Global Long-acting Beta Agonists Revenue Market Share by Type (2020-2025)
 Table 57. Global Long-acting Beta Agonists Revenue Market Share by Type (2026-2031)
 Table 58. Global Long-acting Beta Agonists Price (US$/Unit) by Type (2020-2025)
 Table 59. Global Long-acting Beta Agonists Price (US$/Unit) by Type (2026-2031)
 Table 60. Global Long-acting Beta Agonists Sales (K Units) by Application (2020-2025)
 Table 61. Global Long-acting Beta Agonists Sales (K Units) by Application (2026-2031)
 Table 62. Global Long-acting Beta Agonists Sales Market Share by Application (2020-2025)
 Table 63. Global Long-acting Beta Agonists Sales Market Share by Application (2026-2031)
 Table 64. Global Long-acting Beta Agonists Revenue (US$ Million) by Application (2020-2025)
 Table 65. Global Long-acting Beta Agonists Revenue (US$ Million) by Application (2026-2031)
 Table 66. Global Long-acting Beta Agonists Revenue Market Share by Application (2020-2025)
 Table 67. Global Long-acting Beta Agonists Revenue Market Share by Application (2026-2031)
 Table 68. Global Long-acting Beta Agonists Price (US$/Unit) by Application (2020-2025)
 Table 69. Global Long-acting Beta Agonists Price (US$/Unit) by Application (2026-2031)
 Table 70. GSK Company Information
 Table 71. GSK Description and Business Overview
 Table 72. GSK Long-acting Beta Agonists Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 73. GSK Long-acting Beta Agonists Product
 Table 74. GSK Recent Developments/Updates
 Table 75. AstraZeneca Company Information
 Table 76. AstraZeneca Description and Business Overview
 Table 77. AstraZeneca Long-acting Beta Agonists Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 78. AstraZeneca Long-acting Beta Agonists Product
 Table 79. AstraZeneca Recent Developments/Updates
 Table 80. Chiesi Company Information
 Table 81. Chiesi Description and Business Overview
 Table 82. Chiesi Long-acting Beta Agonists Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 83. Chiesi Long-acting Beta Agonists Product
 Table 84. Chiesi Recent Developments/Updates
 Table 85. Boehringer Ingelheim Company Information
 Table 86. Boehringer Ingelheim Description and Business Overview
 Table 87. Boehringer Ingelheim Long-acting Beta Agonists Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 88. Boehringer Ingelheim Long-acting Beta Agonists Product
 Table 89. Boehringer Ingelheim Recent Developments/Updates
 Table 90. Novartis Company Information
 Table 91. Novartis Description and Business Overview
 Table 92. Novartis Long-acting Beta Agonists Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 93. Novartis Long-acting Beta Agonists Product
 Table 94. Novartis Recent Developments/Updates
 Table 95. Teva Company Information
 Table 96. Teva Description and Business Overview
 Table 97. Teva Long-acting Beta Agonists Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 98. Teva Long-acting Beta Agonists Product
 Table 99. Teva Recent Developments/Updates
 Table 100. Organon Company Information
 Table 101. Organon Description and Business Overview
 Table 102. Organon Long-acting Beta Agonists Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 103. Organon Long-acting Beta Agonists Product
 Table 104. Organon Recent Developments/Updates
 Table 105. Key Raw Materials Lists
 Table 106. Raw Materials Key Suppliers Lists
 Table 107. Long-acting Beta Agonists Distributors List
 Table 108. Long-acting Beta Agonists Customers List
 Table 109. Long-acting Beta Agonists Market Trends
 Table 110. Long-acting Beta Agonists Market Drivers
 Table 111. Long-acting Beta Agonists Market Challenges
 Table 112. Long-acting Beta Agonists Market Restraints
 Table 113. Research Programs/Design for This Report
 Table 114. Key Data Information from Secondary Sources
 Table 115. Key Data Information from Primary Sources
 Table 116. Authors List of This Report


List of Figures
 Figure 1. Product Picture of Long-acting Beta Agonists
 Figure 2. Global Long-acting Beta Agonists Market Value Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global Long-acting Beta Agonists Market Share by Type: 2024 & 2031
 Figure 4. Serevent Product Picture
 Figure 5. Foradil Product Picture
 Figure 6. Striverdi Product Picture
 Figure 7. Other Product Picture
 Figure 8. Global Long-acting Beta Agonists Market Value by Application (2020-2031) & (US$ Million)
 Figure 9. Global Long-acting Beta Agonists Market Share by Application: 2024 & 2031
 Figure 10. COPD
 Figure 11. Asthma
 Figure 12. Other
 Figure 13. Global Long-acting Beta Agonists Revenue, (US$ Million), 2020 VS 2024 VS 2031
 Figure 14. Global Long-acting Beta Agonists Market Size (2020-2031) & (US$ Million)
 Figure 15. Global Long-acting Beta Agonists Sales (2020-2031) & (K Units)
 Figure 16. Global Long-acting Beta Agonists Average Price (US$/Unit) & (2020-2031)
 Figure 17. Long-acting Beta Agonists Report Years Considered
 Figure 18. Long-acting Beta Agonists Sales Share by Manufacturers in 2024
 Figure 19. Global Long-acting Beta Agonists Revenue Share by Manufacturers in 2024
 Figure 20. Global 5 and 10 Largest Long-acting Beta Agonists Players: Market Share by Revenue in Long-acting Beta Agonists in 2024
 Figure 21. Long-acting Beta Agonists Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
 Figure 22. Global Long-acting Beta Agonists Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Figure 23. North America Long-acting Beta Agonists Sales Market Share by Country (2020-2031)
 Figure 24. North America Long-acting Beta Agonists Revenue Market Share by Country (2020-2031)
 Figure 25. United States Long-acting Beta Agonists Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 26. Canada Long-acting Beta Agonists Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 27. Europe Long-acting Beta Agonists Sales Market Share by Country (2020-2031)
 Figure 28. Europe Long-acting Beta Agonists Revenue Market Share by Country (2020-2031)
 Figure 29. Germany Long-acting Beta Agonists Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 30. France Long-acting Beta Agonists Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 31. U.K. Long-acting Beta Agonists Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 32. Italy Long-acting Beta Agonists Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 33. Russia Long-acting Beta Agonists Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 34. Asia Pacific Long-acting Beta Agonists Sales Market Share by Region (2020-2031)
 Figure 35. Asia Pacific Long-acting Beta Agonists Revenue Market Share by Region (2020-2031)
 Figure 36. China Long-acting Beta Agonists Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 37. Japan Long-acting Beta Agonists Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 38. South Korea Long-acting Beta Agonists Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 39. India Long-acting Beta Agonists Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 40. Australia Long-acting Beta Agonists Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 41. China Taiwan Long-acting Beta Agonists Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 42. Southeast Asia Long-acting Beta Agonists Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 43. Latin America Long-acting Beta Agonists Sales Market Share by Country (2020-2031)
 Figure 44. Latin America Long-acting Beta Agonists Revenue Market Share by Country (2020-2031)
 Figure 45. Mexico Long-acting Beta Agonists Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 46. Brazil Long-acting Beta Agonists Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 47. Argentina Long-acting Beta Agonists Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 48. Middle East and Africa Long-acting Beta Agonists Sales Market Share by Country (2020-2031)
 Figure 49. Middle East and Africa Long-acting Beta Agonists Revenue Market Share by Country (2020-2031)
 Figure 50. Turkey Long-acting Beta Agonists Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 51. Saudi Arabia Long-acting Beta Agonists Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 52. UAE Long-acting Beta Agonists Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 53. Global Sales Market Share of Long-acting Beta Agonists by Type (2020-2031)
 Figure 54. Global Revenue Market Share of Long-acting Beta Agonists by Type (2020-2031)
 Figure 55. Global Long-acting Beta Agonists Price (US$/Unit) by Type (2020-2031)
 Figure 56. Global Sales Market Share of Long-acting Beta Agonists by Application (2020-2031)
 Figure 57. Global Revenue Market Share of Long-acting Beta Agonists by Application (2020-2031)
 Figure 58. Global Long-acting Beta Agonists Price (US$/Unit) by Application (2020-2031)
 Figure 59. Long-acting Beta Agonists Value Chain
 Figure 60. Channels of Distribution (Direct Vs Distribution)
 Figure 61. Bottom-up and Top-down Approaches for This Report
 Figure 62. Data Triangulation
 Figure 63. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Bioinformatics Barcelona

SIMILAR REPORTS

Global Long Acting Beta Agonist Market Insights Forecast to 2030
Short Acting Beta Agonists Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Arformoterol Market Insights Forecast to 2030
Global Inhaled Asthma Medications Market Research Report 2024
Asthma and COPD Drug Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Levosalbutamol Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Inhaler Medicine Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Fluticasone Propionate Inhalers Market Research Report 2024
Global Budesonide Inhaler Market Research Report 2024
Global Salbutamol Market Research Report 2024
Short acting B2 Agonists Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Labetalol Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Drugs for Asthma and COPD Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Ultra Long Acting Beta Agonist Market Research Report 2025
Global Long acting Glucocorticoid Injection Market Research Report 2024
Salbutamol Inhalation Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Long acting Injectable Medications Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Long Term Asthma Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Salbutamol Sulfate Tablets Market Research Report 2024
Drug Inhaler Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

RELATED REPORTS

Global Long-Acting HIV-1 Inhibitors Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-19B19893
Thu Sep 11 00:00:00 UTC 2025

Add to Cart

Global Methylphenidate Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-30B3636
Thu Sep 11 00:00:00 UTC 2025

Add to Cart

Global Soliris Intravenous Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-3H1702
Thu Sep 11 00:00:00 UTC 2025

Add to Cart

Global Mouth Ulcers Drugs Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-13C3384
Wed Sep 10 00:00:00 UTC 2025

Add to Cart

Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions